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Multidrug-resistant tuberculosis (MDR-TB) has become a worldwide problem and a major public health
concern. The mechanisms of resistance are fairly well characterized for most agents, but MDR limits the
therapeutic usefulness of both new and classical medicines against TB. Ethionamide (ETA) is a thioamide
antibiotic and one of the most widely used drugs as second line agent for the treatment of MDR-TB. Over
the years, some studies have emerged to improve the bioavailability of this drug and of its active
metabolites. However, inactive metabolites of ETA are still a major drawback in its application against
TB. Porous silicon (PSi) materials can be applied to improve the dissolution behavior of poorly water-
soluble compounds and to overcome toxicity and other drug-related problems in oral delivery. In the
present work, we have loaded ETA into thermally carbonized-PSi (TCPSi) microparticles and studied
the solubility, toxicity, permeability, and metabolic profiles of the PSi-loaded drug. The solubility and per-
meability of ETA was clearly enhanced after loaded into TCPSi particles at different pH-values. ETA was in
general toxic at concentrations above 0.50 mM to HepG2, Caco-2, and RAW macrophage cells, but the
toxicity was drastically reduced when the drug was loaded into the microparticles. ETA showed a fast
metabolization process in the presence of the TCPSi particles.
In addition, new thiolated metabolites were identified from incubation of ETA-loaded PSi with HepG2
liver cells, which opens new perspectives toward both the understanding of ETA metabolism and the
development of novel ETA-based systems with improved efficacy against MDR-TB.
 2012 Elsevier B.V. All rights reserved.1. Introduction
Multidrug-resistant tuberculosis (MDR-TB) has become a
worldwide problem and a major public health concern. Although
the mechanisms of the resistance are fairly well characterized for
most agents, namely first line agents, the knowledge of all relevant
mechanisms of drug resistance in TB is still limited [1]. One-third
of the world’s population is currently infected with tuberculosis
(TB), and about nine million new cases occur every year [2]. In
addition, about two million deaths from TB occur per year, and
TB is also the leading killer infection among individuals infected
with HIV. MDR-TB can be classified into three different categories:
primary resistance – in individuals originally infected with a resis-ll rights reserved.
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e), helder.santos@helsinki.fitant strain of TB; acquired resistance – in individuals originally in-
fected with a susceptible strain that evolves to become resistant to
medication; and mixed resistance – when the two aforementioned
types of resistance are present [1,3,4].
Ethionamide (ETA, 1 in Fig. 1) is a thioamide antibiotic and one
of the most widely used drugs as second line agent for the treat-
ment of MDR-TB. The mode of action of the activated form of ETA
is via inhibition of the inhA gene product, enoyl-ACP reductase
[5,6]. ETA is activated by a KatG-independent mechanism leading
to the formation of an S-oxide metabolite (ETA-SO, 2 in Fig. 1)
[7,8]. In vivo studies both in mammals and bacteria suggest that
ETA-SO retains the biological activity of the parent drug [9], which
is in line with the fact that ETA andmany current antimycobacterial
agents require some form of cellular activation corresponding to
the oxidative, reductive, or hydrolytic unmasking of active groups
[10–12]. However, other metabolites for ETA (with less therapeutic
importance) have been identified, such as ETA-nitrite (2-ethyl-4-
carboxypyridine), ETA-aldehyde (2-ethyl-4-aldehydopyridine),
and ETA-OH (2-ethyl-4-hydroxymethylpyridine) [13–16].
Over the years, some studies have emerged to improve the
bioavailability of ETA. For example, the use of gatifloxacin in
Fig. 1. Chemical structures of ETA 1 and ETA-SO 2.
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week treatment period [17], and the effect of food, orange juice,
or anti-acids on the absorption of a single oral 500-mg dose of
ETA in healthy volunteers [18] have been tested. Furthermore,
pharmacokinetic parameters of ETA following multiple oral doses
have also been evaluated [19].
ETA modification or encapsulation has also been studied with
the aim of improving the drug’s efficacy against MDR-TB. For in-
stance, Cardoso and co-authors synthesized and characterized
oxazolinyl and N-hydroxyalkyl-ETA derivatives, based on the fact
that those groups possess anti-TB activity [20]. ETA was also
absorbed into different colloidal systems (nanocapsules and nano-
spheres), through the alleged formation of a saline bridge between
the conjugated acid of ETA and the carboxylate anions of the poly-
mer’s outer surface [21].
To the best of our knowledge, porous silicon (PSi) materials
have not been tested yet as possible ETA delivery systems. PSi
has been used in several biomedical applications ranging from
microdevices for therapeutic use [22], chemical and biological sen-
sors [23], to the improvement of the dissolution of poorly water-
soluble compounds [24–28]. PSi has also emerged as a versatile
material for drug delivery and targeting [29–31], as a drug carrier
able to overcome problems associated with oral drugs like toxicity,
poor solubility, or sub-optimal pharmacokinetics [30,32]. Further-
more, the PSi surfaces can be easily modified for imaging purposes
[33–35], which are biocompatible with multiple cell lines [33–37],
and have been shown to efficiently improve delivery of peptides
and small interfering RNAs [38–40].
The present work was devoted to study the behavior of ETA-
loaded PSi microparticles in terms of (a) the dissolution pattern
of the loaded drug; (b) cytotoxicity of the drug-loaded particles
on human colon carcinoma (Caco-2), human hepatoblastoma
(HepG2), and RAW 264.7 murine macrophage cells; (c) drug per-
meability across biological barriers, using the Caco-2 cell system;
and (d) ETA metabolites arising from drug-loaded PSi microparti-
cles incubated with HepG2 cells. Findings are described below
and provide new perspectives toward the development of novel
approaches for the treatment of MDR-TB.2. Materials and methods
2.1. Production of the TCPSi microparticles
The detailed preparation of the particles used has been de-
scribed elsewhere [25,30,36,41]. Briefly, silicon wafers Sih100i of
p+-type, with resistivity values of 0.008–0.020X cm, were used in
the preparation of the thermally carbonized-PSi (TCPSi) microparti-cles. The TCPSi particles were prepared by anodizing the wafers
with a current density of 50 mA cm2 in hydrofluoric acid–ethanol
mixture (HF:EtOH, 1:1). The process was performed in the dark.
Free-standing films were obtained by sharply increasing the cur-
rent. The free-standing PSi films were ball milled after the anodiza-
tion. The milled films were dry-sieved with a mesh with nominal
pore sizes of 25 and 53 lm. The milling and sieving cycles were re-
peated several times to achieve the desired particle sizes. After the
dry-sieving, the particles were rinsed with EtOH on the mesh in or-
der to remove small agglomerates. Prior to any surface treatments,
the particles were treated with HF to remove the oxides formed
during the milling. The particles were dried for 1 h at 65 C.
2.2. Characterization of TCPSi microparticles
The porous properties of the TCPSi microparticles produced
were characterized with N2 adsorption/desorption measurements
on a Tristar 3000 (Micromeritics) instrument at 196 C. The parti-
cle characterization was performed in terms of average pore diam-
eter (D), pore volume (V), and is the specific surface area (As). The D
values were calculated from the desorption branch using the
Barrett–Joyner–Halenda (BJH) theory [42], and As and Vwere calcu-
lated from the desorption branch using the Brunauer–Emmett–
Teller (BET) theory [43].
The surface morphologies of the unloaded and loaded particles
were studied by scanning electron microscopy (SEM; Zeiss DSM
962, Carl Zeiss, Oberkochen, Germany). The samples were sputter
coated with platinum before the imaging.
2.3. Loading of ETA into TCPSi microparticles
Drug loading was performed from an ETA solution in acetone
(20 mg/mL) heated to 60 C in a water bath. TCPSi microparticles
(250 mg) were added into the hot solution of ETA and kept under
gentle magnetic stirring for 1 h. The particles were then vacuum
filtered from the solution and dried at 65 C overnight.
Drug loading was determined by thermogravimetry (TG) on a
TGA-7 instrument (Perkin Elmer Inc., MA, USA) with a heating rate
of 20 C/min under a synthetic air purge gas flow of 200 mL/min.
TG results indicated a drug loading of approx. 5.4 wt.%. Similar val-
ues were also obtained from high-performance liquid chromatog-
raphy (HPLC) quantification of ETA released from the particles
(see further below).
2.4. ETA release experiments
Dissolution experiments of pure ETA and ETA-loaded TCPSi
microparticles were performed using a modified USP paddle meth-
od [44]. Buffer solutions used were 100 mL of 10 Hank’s buffered
salt solution (HBSS) in either 10 mM 2-(N-morpholino)ethanesul-
fonic acid, MES (pH 5.5), or 10 mM 4-(2-hydroxyethyl)-1-piperaz-
ineethanesulfonic acid, HEPES (pH 7.4). Pure ETA and drug-loaded
TCPSi microparticles were weighed directly into open gelatin cap-
sules. A small magnet was used as a sinker and stirrer inside each
capsule, and capsule contents put under stirring at 300 rpm and
37 C. All the experiments were performed at least in triplicate un-
der sink conditions. Aliquots were collected at given time points
for subsequent quantification of the soluble drug by HPLC and
the sample volume withdrawn replaced by fresh pre-warmed
buffer.
2.5. Viability tests cell lines and cultures
The in vitro tests were performed with differentiated and non-
differentiated human colon carcinoma (Caco-2), human hepato-
blastoma (HepG2), and RAW 264.7 murine macrophage cells, all
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cultured in 75 cm2 culture flasks (Corning Inc. Life Sciences, USA)
using Dulbecco’s modified Eagle’s medium (DMEM, EuroClone,
S.p.A., Italy) supplemented with 10% fetal bovine serum (FBS, Gib-
co, Invitrogen, USA), 1% non-essential amino acids, 1% L-glutamine,
penicillin (100 IU/mL), streptomycin (100 lg/mL) (all from Euro-
clone, S.p.A., Italy), and also 1% sodium pyruvate (Invitrogen, CA,
USA) in the particular case of HepG2 cells.
Cell cultures were maintained at 37 C in 5% CO2 atmosphere
and 95% relative humidity (BB 16 gas incubator, Heraeus Instru-
ments GmbH, Germany). Growth media were changed every other
day until the time of use. Prior to each test, the cells were
harvested using 0.25% trypsin (Euroclone S.p.A., Italy) in 0.05 mM
ethylenediamine tetraacetic acid (EDTA; Sigma–Aldrich, USA) in
phosphate-buffered saline (PBS, Invitrogen, USA) solution and di-
luted to a density of 2–5  105 cells/mL. Suspended cells were
seeded into 6-, 12-, or 96-well plates (PerkinElmer Inc., USA) and
incubated for about 24–48 h to reach confluency.
The number of viable cells in culture was quantified based on
the amount of ATP produced by metabolically active cells
(CellTiter-Glo Luminescence Cell Viability Assay, Promega, USA).
Cells cultured in 96-well plates, as described above, were washed
twice with 100 lL of HBSS (pH 7.4). Then, 100 lL of pure ETA or
ETA-loaded TCPSi suspensions (in HBSS) were added to each well
and the plates incubated at 37 C for 24 h. After incubation, the
wells were washed three times with HBSS to remove excess of pure
drug or microparticles, and the plates were equilibrated at room
temperature for about 30 min. Then, 100 lL of the developing
reagent was added to each well, according to manufacturer’s
instructions, and the resulting luminescence was measured on a
Wallac 1450 MicroBeta/Trilux luminescence counter (PerkinElmer
Inc., MA, USA). Cell viability was expressed as the percentage of
luminescence measured for the negative control (only buffer).
Triton X-100 (Sigma–Aldrich, USA) was used as a positive control
for cytotoxic activity [36].
2.6. Caco-2 permeability experiments
The permeability of pure ETA (control) or ETA-loaded TCPSi
microparticles was studied across Caco-2 cell monolayers. The cells,
grown as previously described, were seeded on 12-Transwell cell
culture inserts (polycarbonate membranes, pore size 0.4 lm,
growth area 1.12 cm2, Corning Inc. Life Sciences, USA) to formmon-
olayers that were used 21–28 days after seeding. Cell monolayers
were rinsed twice with HBSS (pH 7.4) and equilibrated in the
transport buffers under experimental conditions for 30 min. The
permeability of the test samples (pure ETA and ETA-loaded micro-
particles) was assessed in apical-to-basolateral direction at an api-
cal pH of 5.5 and basolateral pH of 7.4, at 37 C with orbital shaking
(50 rpm). Control experiments (untreated cells) were performed in
parallel. Transepithelial electrical resistance (TEER) was measured
using a Millicell ERS Voltohmmeter (Millipore Corp., Bedford, MA,
USA), andmonolayers with TEER values below 250X cm2were dis-
carded. The apical solution was changed to HBSS to which was
added pure ETA (ca. 111 lg) or loaded TCPSi microparticles
(2.0 mg). Aliquots (100 lL) from the basolateral compartment were
collected at given time points for posterior drug quantification by
HPLC withdrawn replaced by fresh pre-warmed buffer. Monolayer
integrity after each experiment was determined by TEER and al-
lowed confirming that, under the experimental conditions used,
Caco-2 monolayers were not damaged (data not shown).
2.7. Metabolization of ETA in HepG2 cells
In order to compare the degree of drug metabolization in both
pure ETA and ETA-loaded TCPSi microparticles, HepG2 cells, grownas described above, were seeded in 6-well plates (Corning Inc. Life
Sciences, USA) or in 12-Transwell cell culture inserts, in all cases
using HBSS buffer at pH 7.4. Pre-dissolved ETA (control solutions)
or ETA-loaded TCPSi microparticles were added to cells. Aliquots
(100 lL) were collected at different time points, the withdrawn re-
placed by fresh pre-warmed buffer, and the samples analyzed by
LC–EIS/MS as described below.
2.8. HPLC quantification of ETA
ETA concentrations in the samples were analyzed by HPLC
(Agilent 1100 Series, Agilent Technologies, Germany) using an Agi-
lent G1365B multiple wavelength detector, an Agilent G1367A
well-plate autosampler, an Agilent G1316A thermostatted column
compartment (at 25 C), an Agilent G1312A binary pump, and an
Agilent G1379A microvacuum degasser. Sample volumes of 20 lL
were injected on a Gemini C18 reversed-phase column (100 
4.6 mm; 3 lm particle diameter; Phenomenex, USA) and eluted
isocratically, using 90% acetonitrile and 10% aqueous trifluoroace-
tic acid (0.1%, pH 2.0) as mobile phase, at a flow rate of 1.0 mL/
min. Volumes of 20 lL of the samples were injected for analysis.
ETA presented a retention time of 2.9 min under these conditions
(detection at k = 220 nm).
2.9. LC/UV–DAD/ESI-MSn analyses
LC/DAD/ESI-MSn analyses were performed on a Finnigan Sur-
veyor Plus HPLC (Thermo Scientific, USA) instrument equipped
with a diode-array detector and a mass detector. The HPLC system
consisted of a quaternary pump, an autosampler, a degasser, a pho-
todiode-array detector, and a thermostatted column compartment
that was kept at 25 C. An end-capped Merck Purospher C-18 col-
umn (150 mm  4 mm; 5 lm particle diameter, end-capped) was
used and the elution gradient was 0% B (0 min) to 100% B
(30 min), with A = 0.1% (v/v) aqueous trifluoroacetic acid and
B = acetonitrile, both previously degassed and filtered. The column
was re-equilibrated for 10 min between injections.
The mass detector was a Finnigan Surveyor LCQ XP MAX qua-
druple ion trap mass spectrometer (MS) equipped with an ESI
interface. Control and data acquisition was carried out with Xcali-
bur software (ThermoFinnigan, San Jose, USA). Nitrogen above
99% purity was used and the gas pressure was 520 kPa (75 psi).
The instrument was operated in positive-ion mode with electro-
spray ionization (ESI) needle voltage, 5.00 kV; ESI capillary temper-
ature was 325 C; Full scans covered the mass rangem/z from 50 to
2000. MS/MS data were simultaneously acquired for the selected
precursor ion. Collision-induced dissociation CID-MS/MS experi-
ments were performed using helium as the collision gas with
25–35 eV of energy.
2.10. Statistical analysis
Results are given as average ± standard deviation (SD) from at
least three independent experiments. Data were analyzed by One-
way Analysis of Variance (ANOVA), followed by Dunnett’s HSD post
hoc test. These tests were performed using GraphPad Prism v. 5.01
(GraphPad Software, CA, USA), and the level of significance was set
at a probability of ⁄p < 0.05, ⁄⁄p < 0.01, and ⁄⁄⁄p < 0.001.3. Results and discussion
3.1. Characterization of TCPSi microparticles
The physicochemical properties of the TCPSi microparticles
used in this study were studied. The particles presented a pore size
Fig. 2. SEM micrographs of TCPSi microparticles. Scale bars are 200 lm and 20 lm
for the main frame and the inset, respectively.
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area of 225 m2/g. Scanning electron microscopy (SEM) analysis ofFig. 4. Cell viability (ATP production) determined by the CellTiter-Glo luminescent assa
microparticles. Error bars represent mean ± SD (nP 3). ⁄p < 0.05, statistically significantthe particles’ morphology allowed observing that the PSi particles
have an angular structure with a size fraction of 25–53 lm, as
shown in Fig. 2.
3.2. Physicochemical properties of pure and loaded drug
The solubility of pure ETA in aqueous buffer at pH 1.2 was 4 mg/
mL, but decreased to 741 lg/mL in the pH range of 5.5–7.4, which
concurs with the weakly basic nature of the drug.
The percentage of ETA released and dissolved over time was
measured both for the pure drug and for ETA-loaded TCPSi micro-
particles, at pH 5.5 and 37 C, as shown in Fig. 3. Maximal drug dis-
solution was clearly reached faster when using the drug-loaded
TCPSi microparticles, as compared to pure ETA. Similar results
were obtained at pH 7.4 (data not shown). For the ETA-loaded
TCPSi microparticles, the maximal drug dissolution was reached
at 3 and 1 min for pH 5.5 and 7.4, respectively, whereas for the
pure drug, it took 60 and 40 min for pH 5.5 and 7.4, respectively.
3.3. Cell viability and ATP production
Fig. 4A shows the ATP production in RAW 264.7 macrophages,
Caco-2, and HepG2 cells in the presence of different concentrations
of pure ETA. As expected, increasing the ETA concentration led to
increased toxicity to the different cell lines used. Thus, ETA wasy after 24 h incubation (pH 7.4, 37 C) with (A) pure ETA and (B) ETA-loaded TCPSi
differences found compared to the control groups.
Fig. 6. LC–ESI/MS analysis of free ETA (0.25 mM) after 100-min incubation with HepG2 cells at 37 C and pH 7.4. Top: chromatogram (UV–Vis detection at k = 340 nm);
bottom: mass spectra of major peaks, eluted at ca. 10 min (left) and at ca. 11 min (right). (For interpretation of the references to color in this figure legend, the reader is
referred to the web version of this article.)
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trations up to 0.10 mM or 0.25 mM, respectively. Interestingly,
the concentration threshold was higher in the case of HepG2 cells,
to which ETA was non-toxic at concentrations up to 0.75 mM.
Fig. 4B shows the ATP production in RAW 264.7 macrophages,
Caco-2, and HepG2 cells in the presence of different amounts of
ETA-loaded TCPSi microparticles. As in the case of pure drug, also
increasing amounts of the TCPSi suspensions led to increased tox-
icity to the tested cells. Nevertheless, suspensions of ETA-loaded
TCPSi microparticles up to 0.15 mg/mL (0.90 mM of ETA) kept via-
bility of both RAW 264.7 macrophages and Caco-2 cells above 80%,
while showing no toxicity toward HepG2 cells up to 0.25 mg/mL
(1.5 mM of ETA), which shows a clear improvement on the drug
threshold toxicity when loaded to the particles when compared
to pure drug only. This is probably because the loaded drug is in
a first stage protected by the particles avoiding strong drug–cell
interactions reducing the direct exposure of the drug to the cellsand thus, reducing significantly the cytotoxicity. In later stages,
the drug released from the pores of the particles is fully available
for cell interactions leading to an increase in cytotoxicity. Impor-
tantly, in either of the above mentioned situations, the drug–cell
interactions are minimized somewhat by the presence of the TCPSi
particles when compared to pure drug alone, which reduces signif-
icantly the drug threshold toxicity.
3.4. Permeability across Caco-2 monolayers
Fig. 5 shows the permeability of pure ETA and ETA-loaded TCPSi
microparticles across Caco-2 monolayers. The permeation of ETA
was studied both using the pure drug and TCPSi particles loaded
with an equal amount of the drug. The permeation of ETA released
from the TCPSi particles across Caco-2 cells was faster than that of
the pure drug: after 20 min, the permeation of the released drug
was already eleven-fold than that of the pure drug. A rough
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13  105 and 97  105cm/s for pure ETA and ETA-loaded TCPSi,
respectively. This represents more than a seven-fold increase in
the apparent permeability of pure ETA across the Caco-2 monolay-ers, when using drug-loaded TCPSi microparticles under the exper-
imental conditions studied. Such increase in ETA permeation is
probably due enhanced solubility followed by fast release of the
loaded drug. Therefore, use of ETA-loaded TCPSi microparticles
Fig. 9. MS-fragmentation spectrum for the species detected atm/z 154 and the structures proposed for these species and their fragments (m/z 124). (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article.)
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tion, thus increasing the net absorption and respective drug
permeation [32,46].3.5. Metabolization of ETA in HepG2 cells
Most of the literature on the subject reports that ETA must be
activated before hitting its cellular target [47], through S-oxidation.
Though ETA can be oxidized to its sulfoxide (ETA-SO, 2) in the liver,
it has been suggested that the drug is mainly activated by the path-
ogen itself [7,14,16,48]. Thus, ETA seems to be mainly activated by
the mycobacterial enzyme, EtaA, a flavin-containing monooxygen-
ase, via an unstable, doubly oxidized, sulfinate intermediate 3; this
reactive intermediate undergoes further conversions to finally
yield 2-ethyl-4-amidopyridine, 4, possibly via the nitrile interme-
diate 5.
In the present study, we performed a comparative analysis of
ETA metabolic degradation within HepG2 cells, using both the free
drug and drug-loaded TCPSi microparticles. Although HepG2 cells
lack some liver enzymes, and obviously mycobacterial enzymes
as well, they provide a simple medium to test the effect of the
particles on the drug metabolic degradability.
In order to identify the metabolites formed under the
conditions employed, an LC–ESI/MS study was undertaken, using
samples of both free and loaded drug after incubation with HepG2
cells for 100 min. Fig. 6 shows the results from incubation of free
ETA. Two major bands where observed in the chromatogram: the
first was eluted at ca. 10 min and the second at ca. 11 min. MS
analysis of the eluted bands allowed to ascribe the first band to
undegraded ETA (m/z of ETA’s quasi-molecular ion, [M+H]+ 
167), whereas the second band was associated to a set of three
metabolites with m/z of 114, 154, and 226.
Fig. 7 shows the chromatogram and mass spectra obtained in
the LC–ESI/MS analysis of ETA degradation after 100-min incuba-
tion of ETA-loaded TCPSi microparticles with HepG2 cells. Compar-
ing the chromatogram obtained in this analysis (Fig. 7, top) with
that previously shown for the incubation of free ETA (Fig. 6, top),
it is clear that ETA metabolization is substantially more extensive
when the drug is loaded into the TCPSi microparticles when com-
pared to free drug: the ETA peak eluted at ca. 10 min is practically
undetectable in the chromatogram shown in Fig. 7 (top). In turn,
the band eluted at ca. 11 min is prominent and again associated
to three species with m/z of 114, 154, and 227.
A preliminary structural identification of the three species
arising from ETA incubation with HepG2 cells was undertaken by
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Fig. 12. (A) HPLC chromatograms of pure ETA and loaded ETA into TCPSi microparticles after 100 min of incubation with HepG2 cells at pH 7.4 and 37 C. Similar amounts of
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Fig. 13. Analysis of the products after metabolization of ETA-loaded TCPSi microparticles with HepG2 cells at pH 7.4 and 37 C, after 100 min incubation time. LC
chromatogram (k = 340 nm) and mass spectrum of pure ETA and the resulting products with molecular ion [M+H+] atm/z 114, 154, 226, 145, 185, and 288. (For interpretation
of the references to color in this figure legend, the reader is referred to the web version of this article.)
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trum obtained for the species detected at m/z 114 that is proposed
to correspond to the quasi-molecular ion of 4-formylpiperazine,
which is compatible with its fragmentation to the molecular ion
of pyridine (m/z 79) and the quasi-molecular ion of 4-methyl-
1,4-dihydropyridine.
Similarly, Fig. 9 shows the fragmentation suffered by the species
detected at m/z 154, which is proposed to be 2-ethyl-4-mercap-
tomethylpyridine, which is compatible with the quasi-molecular
ion of 4-thioformylpyridine at m/z 124.
Finally, it was postulated that the species detected at m/z 227
was the quasi-molecular ion of a 4-formylpiperazine (m/z 113) di-
mer, which was supported by the fragmentation spectrum ob-
tained for that species and where the only fragment was
detected at m/z 114 (Fig. 10).
To provide proof that the species observed in the MS study
above did arise from ETA incubation with HepG2 cells, and not
from fragmentation of the drug in the course of MS analysis, the
MS2 spectrum of pure ETA was obtained under identical conditions
as the ones described above (Fig. 11).
The results above indicate that ETA is fragmented into minor
species detected atm/z 134, probably corresponding to the nitrile
derivative, similar to 5, formerly proposed by Vanneli and co-
workers as a possible intermediate of EtaA-mediated metabolism
of ETA [16]. The absence of C-2 ethyl group was also reported by
the same authors for the analogues of ETA that are oxidized by
the purified flavoprotein. The major fragment, however, was de-
tected at m/z 140, possibly corresponding to the molecular ion of
aminomercaptomethylpyridine, that is, the reduced thiol deriva-
tive of desethyl-ETA.
Interestingly, the amount of pure ETA converted into its metab-
olites after 100 min was very low. In contrast, the ETA loaded into
TCPSi microparticles was more extensively metabolized during the
same time period, regarding both number and amount of metabo-
lites (see Fig. 12). Although the phenomenon is not fully under-
stood yet, it is probable that the surface chemistry of the TCPSi
particles triggered some drug–particle surface reactions inducing
metabolite formation of the drug loaded inside the pores [27]. This
needs, however, to be confirmed in future studies.
Fig. 12A shows the study of ETA-loaded TCPSi particles after
100 min (transport experiments). Based on the intensity and pro-
file of HPLC peaks, we postulate that there is a direct relationship
between what is observed in HPLC and LC–MS results. The princi-
pal compounds (1, 3 and 4) were identified and a peak at m/z 141
(2, Fig. 12B) was similar to the principal ion fragment of pure ETA
(see Fig. 11). However, it is likely that this compound was formed
during the transport experience and not during the analysis by LC–
ESI/MS.
The metabolization of ETA in HepG2 cells (Fig. 13) yielded a
new group of compounds at retention time of ca. 13 min (again,
at 10 min, it is observed ETA, and at 11 min, it is observed the three
metabolites identified in Figs. 8–10). In this area, it is possible to
observe the metabolite ETA-SO (2, m/z 185) and two other, corre-
sponding to the new structures (m/z 288 and m/z 144). However,
it was not possible to fragment these three compounds, although
we assume that there is a relationship between the structures pro-
posed for the other two new compounds of the parent drug at the
retention time of ca. 11 min.4. Conclusions
In the present work, we have loaded ETA into TCPSi microparti-
cles and studied the solubility, toxicity, permeability, and
metabolic profiles of ETA loaded into the particles. The physico-
chemical and metabolic properties of the anti-tubercular drugETA were favorably modulated by loading the drug into the TCPSi
microparticles. The solubility and permeability of ETA was clearly
enhanced after loaded into TCPSi particles at different pH-values.
ETA was in general toxic at concentrations above 0.50 mM to
HepG2, Caco-2, and RAW macrophage cells, but the toxicity was
drastically reduced when the drug was loaded into the microparti-
cles. ETA showed a fast metabolization process in the presence of
the TCPSi particles possibly triggered by the drug–surface particle
interactions. New thiolated metabolites were identified from incu-
bation of ETA-loaded TCPSi microparticles with HepG2 liver cells,
which is relevant for the future development of ETA derivatives
with improved therapeutic action and reduced propensity to elicit
resistance by Mycobacteria.Acknowledgments
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